Is there such a thing as a not-for-profit pharmaceutical company?

What are “neglected tropical diseases”?

How can you address global health inequities in access to medicines?

These are just a few of the many incisive questions that our latest episode of Philanthropod explores.

In episode 2 of Season 8 meet Mark Sullivan AO, Managing Director and Founder of Medicines Development for Global Health (MDGH). MDGH is an independent not-for-profit company dedicated to the development of medicines for neglected diseases that primarily affect people living in poverty.

The majority of new medicines are developed for diseases that are prevalent in high-income countries as the potential returns on an approved medicine offset the high cost and risk of development. This model disadvantages the world’s poorest populations – according to the WHO, an estimated two billion people do not have access to even the most basic of essential medicines.

Responding to this deep inequity in global health, in 2005, Mark founded MDGH. Since its inception MDGH has demonstrated that it is possible to assemble the resources, collaborators and financing required to develop and register new medicines for infectious diseases in a not-for-profit company. In fact, in 2018, MDGH became the first solo not-for-profit company to achieve FDA approval for a novel medicine when they registered moxidectin, the first new treatment for river blindness (onchocerciasis) in 20 years.

Join Philanthropod’s host, Anubha Rawat, in conversation with Mark as they discuss Mark’s pioneering journey throughout the pharmaceutical industry, the importance of working with local NGOs, communities and health providers to distribute medicines, and navigating critical regulatory systems with major global health bodies such as the FDA (US Food and Drug Administration) and WHO (World Health Organisation).

To learn more about MDGH follow the link: https://www.medicinesdevelopment.com/

Hosted on Acast. See acast.com/privacy for more information.